WO2024236452 - PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER
National phase entry:
Publication Number
WO/2024/236452
Publication Date
21.11.2024
International Application No.
PCT/IB2024/054597
International Filing Date
11.05.2024
Title **
[English]
PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER
[French]
DÉRIVÉS DE PYRAZOLO[4,3-F]QUINAZOLINE EN TANT QUE MODULATEURS DE MUTANTS KRAS G12D UTILES POUR LE TRAITEMENT DU CANCER
Applicants **
JAZZ PHARMACEUTICALS IRELAND LTD.
Inventors
JACKSON, Paula
AYLOTT, Helen Elizabeth
JONES, Clifford D
BHAMRA, Inder
RYAN, James
LENG, Daniel J
HO, Kelvin
Priority Data
2307077.4
12.05.2023
GB
2319678.5
20.12.2023
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7087 | |
| EPO | Filing, Examination, Granting | 30685 | |
| Japan | Filing, Examination, Granting | 2760 | |
| South Korea | Filing, Examination, Granting | 3256 | |
| USA | Filing, Examination, Granting | 11140 |
Total:
54,928
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
This invention relates to compounds that may be useful for inhibiting RAS proteins. More specifically, this invention relates to compounds for inhibiting a broad spectrum of KRAS mutant proteins, including KRAS G12D. The compounds of the invention may therefore be used in treating conditions mediated by KRAS proteins. For example, the compounds may be used in treating cancer.[French]
Cette invention concerne des composés qui peuvent être utiles pour inhiber des protéines RAS. Plus spécifiquement, cette invention concerne des composés pour inhiber un large spectre de protéines mutantes KRAS, notamment KRAS G12D. Les composés de l'invention peuvent donc être utilisés dans le traitement d'états pathologiques médiés par des protéines KRAS. Par exemple, les composés peuvent être utilisés dans le traitement du cancer.